Coursera Inc
Change company Symbol lookup
Select an option...
COUR Coursera Inc
SIMO Silicon Motion Technology Corp
CGNX Cognex Corp
SNTG Sentage Holdings Inc
XNXNX Nuveen New York Select Tax Free Income Portfolio
ITRI Itron Inc
NMZ Nuveen Municipal High Income Opportunity Fund
WTER Alkaline Water Company Inc
CASA Casa Systems Inc
PVBC Provident Bancorp Inc (Maryland)

Consumer Discretionary : Diversified Consumer Services | Small Cap Growth
Company profile

Coursera, Inc. provides Coursera, a platform that connects learners, educators and institutions, providing educational content that is accessible and relevant. The Company's segments include Consumer, Enterprise and Degrees. Coursera provides a range of learning offerings, including Guided Projects, Courses, Specializations, Certificates and Degrees. Its offerings include for Individuals, Coursera for Enterprise, Coursera for Business, Coursera for Campus and Coursera for Government. Coursera partners with university and industry partners to provide a broad portfolio of content and credentials. Its university partners offer courses across a range of domains, including data science, technology, business, health, social sciences, and arts and humanities. The Company also offers Coursera Plus, a subscription pricing model that gives learners access to over 7,000 courses, Guided Projects, Specializations, and Professional Certificates on Coursera for a monthly or annual fee.

Closing Price
Day's Change
0.34 (2.49%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Aeglea's stock rises after asking the FDA to approve therapy for rare disorder

8:10 am ET April 12, 2022 (MarketWatch)

Shares of Aeglea BioTherapeutics Inc. (AGLE) jumped 14.4% in premarket trading on Tuesday after the company said it asked the Food and Drug Administration to approve an experimental treatment for Arginase 1 deficiency, a rare disorder. Aeglea said it asked the regulator to grant priority review when it submitted the biologics license application for pegzilarginase. "While we have recently received feedback from the FDA expressing disagreement on the substantial evidence of effectiveness of pegzilarginase, we believe based on the totality and compelling nature of our clinical results and the high unmet need that the best path forward for both the ARG1-D community and Aeglea was to proceed with the BLA submission," Anthony Quinn, Aeglea's president and CEO, said in a news release. Aeglea's stock has slipped 48.8% so far this year, while the broader S&P 500 is down 5.8%.

-Jaimy Lee


(END) Dow Jones Newswires

April 12, 2022 08:10 ET (12:10 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.